Opendata, web and dolomites

HepatoRiSK TERMINATED

A new tumor suppressor role for RSK2 in hepatocellular carcinoma

Total Cost €

0

EC-Contrib. €

0

Partnership

0

Views

0

 HepatoRiSK project word cloud

Explore the words cloud of the HepatoRiSK project. It provides you a very rough idea of what is the project "HepatoRiSK" about.

feed    mutating    crispr    worldwide    mechanistic    activates    limited    rsk2    patient    kinases    functionally    genes    hydrodynamic    therapies    genetics    subject    supervision    altogether    acting    function    mechanisms    injection    sequencing    revealed    techniques    me    mechanism    mortality    intervention    vein    cells    elucidate    whereby    genetic    stepping    poor    raf    professor    hepatocellular    assistant    context    hampers    samples    unexpectedly    kinase    combines    cas9    mice    back    uncover    lab    tumor    months    mutations    host    found    basis    ras    model    dependent    reagents    aberrations    tail    editing    molecular    nearly    treatment    inhibitor    independent    mutated    frequently    phenotypic    responsibilities    performed    formal    gene    potently    postdoc    co    biochemical    landscape    cancer    genome    carcinoma    stone    vitro    adult    options    mapped    hypothesize    models    mouse    ranks    validated    partly    inhibit    erk    acute    career    fellowship    suppressor    hcc    liver   

Project "HepatoRiSK" data sheet

The following table provides information about the project.

Coordinator
KOBENHAVNS UNIVERSITET 

Organization address
address: NORREGADE 10
city: KOBENHAVN
postcode: 1165
website: www.ku.dk

contact info
title: n.a.
name: n.a.
surname: n.a.
function: n.a.
email: n.a.
telephone: n.a.
fax: n.a.

 Coordinator Country Denmark [DK]
 Total cost 212˙194 €
 EC max contribution 212˙194 € (100%)
 Programme 1. H2020-EU.1.3.2. (Nurturing excellence by means of cross-border and cross-sector mobility)
 Code Call H2020-MSCA-IF-2014
 Funding Scheme MSCA-IF-EF-ST
 Starting year 2015
 Duration (year-month-day) from 2015-10-01   to  0000-00-00

 Partnership

Take a look of project's partnership.

# participants  country  role  EC contrib. [€] 
1    KOBENHAVNS UNIVERSITET DK (KOBENHAVN) coordinator 212˙194.00

Map

 Project objective

Hepatocellular carcinoma (HCC) ranks third in cancer mortality worldwide. In spite of this, effective treatment options are limited, partly due to a poor understanding of the molecular basis of HCC, which hampers development of targeted therapies. Recently, cancer genome sequencing mapped the landscape of genetic aberrations in HCC and unexpectedly revealed the kinase RSK2 as the most frequently mutated gene in the RAS-RAF-ERK pathway. I hypothesize that RSK2 is a tumor suppressor in HCC by acting as a feed-back inhibitor of the RAS-ERK pathway, since I find that RSK2 mutations are nearly all loss-of-function and that RSK2 loss potently activates ERK kinases in liver cells. The goal of this proposal is to functionally establish RSK2 as a novel and important tumor suppressor in HCC and identify the mechanism(s) whereby RSK2 may feed-back inhibit the RAS-ERK pathway to promote this cancer. This will be achieved through modelling RSK2 loss in liver cells in vitro and in mice. Among other approaches, I will model RSK2-dependent HCC development by mutating genes found co-mutated with RSK2 directly in the adult mouse liver via hydrodynamic tail vein injection of CRISPR/Cas9 reagents, which may cause HCC within months. I will subject cells and mouse models to mechanistic biochemical and phenotypic studies to elucidate the role and mechanism of RSK2 as a tumor suppressor in HCC. Key findings will be validated in HCC patient samples. The work will be performed in the context of my new role as assistant professor in the host lab, where I will be given formal supervision and management responsibilities. The work combines my postdoc experience in cancer genetics with my host´s beyond-state-of-the-art CRISPR/Cas9 genome editing techniques. Altogether, this fellowship has the potential to uncover new mechanisms for targeted intervention in HCC. Furthermore, it will be an important stepping stone for me towards an independent research career.

Are you the coordinator (or a participant) of this project? Plaese send me more information about the "HEPATORISK" project.

For instance: the website url (it has not provided by EU-opendata yet), the logo, a more detailed description of the project (in plain text as a rtf file or a word file), some pictures (as picture files, not embedded into any word file), twitter account, linkedin page, etc.

Send me an  email (fabio@fabiodisconzi.com) and I put them in your project's page as son as possible.

Thanks. And then put a link of this page into your project's website.

The information about "HEPATORISK" are provided by the European Opendata Portal: CORDIS opendata.

More projects from the same programme (H2020-EU.1.3.2.)

ShaRe (2019)

The potential of Sharing Resources for mitigating carbon emissions and other environmental impacts

Read More  

FreeDigital (2019)

The impact of 'free' digital offers on individual behavior and its implications for consumer and data protection laws

Read More  

EOBRECA (2019)

Differential Roles of Estrogens in Obesity-mediated ER+ Breast Cancer Development

Read More  
lastchecktime (2021-03-05 23:35:57) correctly updated